Last reviewed 2026-04-19 · How we verify

CIRAMADOL

Phase 2 active Small molecule

CIRAMADOL is a ciramadol drug. It is currently in Phase 2 development.

CIRAMADOL works by activating the mu-type opioid receptors in the brain, which helps to reduce pain perception.

CIRAMADOL is a small molecule drug that targets the mu-type opioid receptor. It is classified as a ciramadol, but its commercial status and approved indications are unknown. The half-life of CIRAMADOL is approximately 3.85 hours, but its bioavailability and off-patent status are not available. As a mu-type opioid receptor agonist, CIRAMADOL works by binding to and activating these receptors, which are involved in pain modulation. Further information on its development, approval, and commercialization is needed.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CIRAMADOL
Drug class	ciramadol
Target	Mu-type opioid receptor
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Imagine your brain has a volume control for pain. Mu-type opioid receptors are like the volume knob. When CIRAMADOL binds to these receptors, it turns down the volume, making pain feel less intense. This can help relieve pain in people who are suffering from it.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CIRAMADOL CI brief — competitive landscape report
CIRAMADOL updates RSS · CI watch RSS

Frequently asked questions about CIRAMADOL

What is CIRAMADOL?

CIRAMADOL is a ciramadol drug.

How does CIRAMADOL work?

CIRAMADOL works by activating the mu-type opioid receptors in the brain, which helps to reduce pain perception.

What drug class is CIRAMADOL in?

CIRAMADOL belongs to the ciramadol class. See all ciramadol drugs at /class/ciramadol.

What development phase is CIRAMADOL in?

CIRAMADOL is in Phase 2.

What does CIRAMADOL target?

CIRAMADOL targets Mu-type opioid receptor and is a ciramadol.

Drug class: All ciramadol drugs
Target: All drugs targeting Mu-type opioid receptor
Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing